5th Singapore Rehabilitation Conference
Ai Mediq is happy to announce publication of results of clinical trial aimed at evaluation of effects of ReOxy treatment on Cardiopulmonary fitness and metabolic profile in aged NYHA FC II-III Coronary Artery Disease patients.
Recent study performed by international team of researchers from Ireland, Luxembourg and Russia has demonstrated that a 5-week course of treatment by ReOxy Breathing Therapy device is found to be statistically significant in improvement of cardiopulmonary fitness measured by Peak VO2 during an incremental cardiopulmonary test (Bruce and M-Bruce protocols).
The results were delivered during the 5th Singapore Rehabilitation Conference hosted by Academia, Singapore General Hospital campus on 7th and 8th of September 2017 that was attended by more than 300 specialists from the region.
It is very pleasing to see that method developed by Ai Mediq continues to gain traction not only in Europe but in Asia as well. We will continue our joint efforts with our local partner Ai Mediq Asia (Singapore) to further introduce this promising non-invasive and non-pharmacological method of treatment into day-to-day practice of cardiologists all-over the world – Galina Spirina (Chief researcher, Ai Mediq S.A.)
Peak VO2 (also known as VO2 max, maximal oxygen consumption, maximal oxygen uptake, peak oxygen uptake or maximal aerobic capacity) is the maximum rate of oxygen consumption as measured during incremental exercise, most typically on a motorized treadmill.
The abstract can be found on page 82 of the Abstract book in the links section